AllSci News
Incannex advances IHL-42X development strategy following positive Phase 2 obstructive sleep apnea results
Incannex Healthcare, a Melbourne and New York-based clinical-stage biopharmaceutical company, announced an updated clinical development strategy for IHL-42X...
Tempest Therapeutics selects Cincinnati Children's AGCTC for TPST-2003 CAR-T manufacturing partnership
Tempest Therapeutics, Inc. (Brisbane, California; Nasdaq: TPST) selected Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC) (Cincinnati,...
Liminatus Pharma raises USD 4m in best-efforts public offering
Cerritos, California-based Liminatus Pharma (NASDAQ: LIMN) announced the pricing of a best-efforts public offering expected to generate approximately USD...
Insilico Medicine and Liquid AI partner on lightweight AI foundation models for drug discovery
Insilico Medicine, a clinical-stage AI-driven drug discovery company headquartered in Hong Kong, and Liquid AI, a Cambridge, Massachusetts-based AI...
NMPA approves Hansoh’s CD19 mAb inebilizumab for third indication of myasthenia gravis
China’s National Medical Products Administration (NMPA) granted drug registration approval on March 25, 2026, for Xinyue (inebilizumab injection) as a treatment for…
J&J/Nanobiotix’s radioenhancer shows early promise in Phase II for inoperable NSCLC
Nanobiotix and Johnson & Johnson reported early data from the CONVERGE study, a randomized Phase II clinical trial evaluating JNJ-1900 (NBTXR3) as…
Rubedo’s topical GPX4 modulator posts positive Phase I in plaque psoriasis, atopic dermatitis
Rubedo Life Sciences, based in Mountain View, California, reported preliminary results from a Phase I clinical trial of RLS-1496, a topical GPX4…
Pinnacle raises USD 89m in Series B cash for oral peptide programs
Pinnacle Medicines, a biotechnology company headquartered in Shanghai and Doylestown, Pennsylvania, focused on oral peptide drug development, has closed an...
Almirall, Lilly’s Ebglyss maintains skin clearance for up to four years in atopic dermatitis
Almirall (BME: ALM) presented interim data from the Phase IIIb ADlong study showing that lebrikizumab maintained skin clearance and itch control for…
Soligenix’s dusquetide granted EC Orphan Drug Designation for Behçet’s disease
Soligenix (Nasdaq: SNGX) announced that the European Commission granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet’s Disease. The…
Novartis strengthens allergy leadership via USD 2b Excellergy acquisition
Novartis has entered into an agreement to acquire Excellergy, Inc., a private US-based biotech developing next-generation anti-IgE therapies, for up to USD...
Myosin’s nanomotor protein-targeted therapy for brain cancer backed with USD 2m Florida grant
Jupiter, Florida-based Myosin Therapeutics has been awarded a USD 2 million grant from the Casey DeSantis Florida Cancer Innovation Fund to support…
BrightGene posts early data for oral dual GLP-1/GIP agonist in obesity
BrightGene Bio-Medical Technology (SSE: 688166), based in Suzhou, China, reported topline Phase I results for BGM0504, an oral GLP-1/GIP dual receptor agonist,…
Ocugen plans Phase III for gene therapy after positive data in geographic atrophy
Ocugen (NASDAQ: OCGN), a Pennsylvania-based biotechnology company, reported 12-month topline data from its Phase II ArMaDa trial showing that OCU410, a one-time…
Innovent’s efdamrofusp alfa meets Phase III endpoint in nAMD
Innovent Biologics (HKEX: 01801), the Suzhou- and San Francisco-based biopharmaceutical company, reported that its dual-target fusion protein efdamrofusp alfa (IBI302) met the…
The AllSci Brief
Free, systematic R&D and deal news. Daily.